Truveta has launched an innovative tool known as Truveta Intelligence, which enables healthcare professionals to receive answers from real-world patient data within minutes. This advancement promises to revolutionize the way researchers interact with patient population data, treatments, and outcomes.
Based in Bellevue, Washington, the company utilizes a vast database of de-identified clinical records from over 130 million patients, accessed through its collaborations with 30 healthcare systems. This represents more than 18% of daily clinical care across the United States.
Unlike traditional AI tools that summarize existing research, Truveta Intelligence directly queries live clinical data, offering insights that could benefit drug manufacturers, health systems, and public health researchers alike. The tool aims to enhance the speed at which drug performance is analyzed, identify variations in patient outcomes, and allow for quicker detection of emerging health trends.
Founded in 2020, Truveta's CEO is Terry Myerson, a former Microsoft executive. The company achieved a valuation exceeding $1 billion following a funding round in January 2025, raising $320 million with contributions from notable entities like Regeneron and Illumina.